immatics biotechnologies
Immatics is a clinical-stage biopharmaceutical company developing PRAME-directed TCR-based immunotherapies — including autologous cell therapies and TCR bispecifics — for patients with PRAME-positive solid tumors such as melanoma, ovarian, lung, and head and neck cancers.
- Company typePublic
- Founded2000
- HeadquartersTübingen, Germany
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What immatics biotechnologies does
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tübingen, Germany, with US operations centered on a ~100,000 sq. ft. R&D and GMP manufacturing facility in the Houston metropolitan area. The company develops T-cell receptor (TCR)-based immunotherapies directed primarily at the PRAME tumor antigen, which is expressed in more than 50 cancer types with limited presence in healthy tissue. Its clinical-stage portfolio spans autologous TCR T-cell therapies (anzu-cel/IMA203, IMA203CD8), TCR bispecifics (IMA401 targeting MAGEA4/8, IMA402 targeting PRAME), and an allogeneic γδ T-cell platform (ACTallo), supported by three proprietary discovery and engineering platforms: XPRESIDENT (mass-spectrometry target identification), XCEPTOR (TCR engineering and validation), and the AI-powered XCUBE in silico matching platform.
immatics biotechnologies firmographics
Firmographics- Name
- immatics biotechnologies
- Legal name
- Immatics N.V.
- Website
- https://immatics.com
- Company type
- Public
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Immatics is a clinical-stage biopharmaceutical company developing PRAME-directed TCR-based immunotherapies — including autologous cell therapies and TCR bispecifics — for patients with PRAME-positive solid tumors such as melanoma, ovarian, lung, and head and neck cancers.
- Ownership category
- akta.pro rank
immatics biotechnologies industry classification
Industry- Product category
- Cancer Immunotherapies
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Dendritic Cell & Other APC-based Therapies (HLAAABAF), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)
Keywords
Where immatics biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Tübingen
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
immatics biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Collaboration/Partnership Revenue: Immatics generates revenue through collaboration agreements with pharmaceutical partners. Revenue declined significantly from $183.1M in 2024 to $56.8M in 2025, reflecting non-cash revenue acceleration recognized in 2024 due to Bristol Myers Squibb's termination of collaboration agreements.
- Future Product Sales: Pre-revenue clinical-stage company planning commercial launch of anzu-cel (PRAME TCR T-cell therapy) for advanced melanoma in H2 2027. Planned commercial cell therapy product targeting ~9,000 addressable patients for first target indications.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
immatics biotechnologies product offering
Product offeringCore offering
Immatics is a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies that target the PRAME tumor antigen across multiple modalities. Its commercial lead asset, anzu-cel (IMA203), is being advanced through a Phase 3 SUPRAME trial for advanced melanoma with a BLA submission targeted in H1 2027 and US commercial launch planned for H2 2027. The portfolio also includes PRAME and MAGEA4/8 TCR bispecifics (IMA402, IMA401), an allogeneic γδ T-cell platform (ACTallo), and proprietary target-discovery and TCR-engineering platforms (XPRESIDENT, XCEPTOR, XCUBE), supported by an in-house GMP cell-therapy manufacturing facility in Houston.
Product overview
Immatics is a clinical-stage biopharmaceutical company developing a broad PRAME-directed immunotherapy franchise with multiple therapeutic modalities. The company's portfolio includes: (1) TCR T-cell therapies (autologous anzu-cel/IMA203, IMA203CD8, and allogeneic platform ACTallo), (2) TCR bispecifics (IMA401 targeting MAGEA4/8, IMA402 targeting PRAME), and (3) enabling technology platforms (XPRESIDENT for target discovery, XCEPTOR for TCR engineering, XCUBE AI-powered platform). The company operates a ~100,000 sq. ft. R&D and GMP manufacturing facility in Houston.
Differentiator
Problem solved
Functional benefit
Products and services
- Anzu-cel (anzutresgene autoleucel, IMA203) Lead PRAME-directed autologous TCR T-cell therapy for advanced cutaneous melanoma and metastatic uveal melanoma, addressing an initial addressable patient population of approximately 9,000 patients.
- IMA203CD8 Next-generation PRAME-directed TCR T-cell therapy engaging both CD8+ and CD4+ T cells, showing 63% ORR in heavily pretreated gynecologic cancers (including 4 complete responses) and 67% ORR in synovial sarcoma.
- IMA402 PRAME-targeted TCR bispecific (TCER) showing favorable tolerability and deep, durable responses in heavily pretreated cancer patients; progressed to Phase 1b dose expansion.
- IMA401 MAGEA4/8-targeted TCR bispecific T-cell engager for solid tumors including NSCLC, head & neck, and bladder cancer; planned for combination use with IMA402 in lung cancer.
- ACTallo (allogeneic TCR T-cell therapy platform) Allogeneic, off-the-shelf TCR T-cell therapy platform based on gene-engineered γδ T cells from healthy donors, designed to eliminate the need for patient-derived cells and enable standardized scalable manufacturing.
- ACTengine (autologous TCR T-cell therapy platform) Proprietary autologous TCR T-cell therapy platform using patient-derived T cells engineered with novel TCRs to detect PRAME peptide on tumors, with manufacturing completed in 7-8 days plus 7-day QC release testing.
- IMA204 (preclinical TCR-T program) Preclinical TCR-T cell therapy targeting the COL6A3 tumor stroma target, designed to engage both CD8+ and CD4+ T cells through a CD8-independent next-generation TCR.
Quantifiable outcome
- 56% confirmed objective response rate (ORR) with 14.6 months median duration of response in advanced melanoma patients treated with anzu-cel
- +4 more outcomes
Companies that use immatics biotechnologies
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
immatics biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
immatics biotechnologies partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Cellular OriginscoreCellular Origins and Immatics announced a collaboration to implement Cellular Origins' automated mobile robotic platform, Constellation®, within Immatics' cell therapy manufacturing processes. The partnership aims to address current manual manufacturing limitations that restrict patient access to approved cell therapies, particularly for solid tumor treatments. Both companies will explore how the Constellation platform can enable scalable and cost-effective production as Immatics advances its programs toward potential regulatory approvals.
- Cellular OriginscoreImmatics, a late-stage clinical biopharmaceutical company focused on precision targeting of PRAME antigens, seeks to automate selected manufacturing operations through this partnership. Cellular Origins, which specializes in manufacturing cell therapies at scale, will provide its automation expertise to support Immatics' cell therapy development pipeline.
- ModernamajorImmatics and Moderna entered strategic research and development collaboration spanning various therapeutic modalities including bispecifics, cell therapy and cancer vaccines. The collaboration combines Immatics' anzu-cel PRAME cell therapy with Moderna's PRAME adaptive immune modulating therapy to further enhance anzu-cel T cell responses with potential to significantly reduce turnaround time and costs through infusion of a much lower cell dose.
- Bristol Myers SquibbmajorBristol Myers Squibb invested $35 million in Immatics to support Immatics' T cell-focused research. The collaboration involved BMS purchasing over 2.4 million shares, with the investment supporting the strengthening collaboration for Immatics' T cell therapy platform.
- Editas MedicinecoreImmatics and Editas Medicine entered strategic collaboration and licensing agreement to combine gamma delta T cell adoptive cell therapies and gene editing technologies.
- MD Anderson Cancer CentermajorImmatics and MD Anderson announced launch of Immatics US, Inc. to develop multiple T-cell and TCR-based adoptive cellular therapies. The partnership established Immatics' US presence and manufacturing capabilities.
Scale indicators13 records
Recent moves6 records
Expansion highlights7 records
immatics biotechnologies competitors and assessment
Company assessmentDirect peers
- Iovance Biotherapeutics: Direct competitor in cell therapy for solid tumors with the approved Amtagvi (lifileucel) in advanced melanoma — the same initial indication Immatics is pursuing with anzu-cel. Highly comparable business model and target patient population.
- Fate Therapeutics: Competitor in off-the-shelf cell therapy with iPSC-derived NK and T-cell programs for solid tumors. Comparable modality and pipeline focus on scalable, allogeneic cancer cell therapies.
- Adaptimmune Therapeutics: Direct competitor developing TCR-based cell therapies (tecelra) for solid tumors, including MAGEA4-directed therapies (analogous to Immatics' IMA401). Closely comparable in modality, target class, and stage of commercialization.
- Cellectis: Competitor in gene-edited allogeneic cell therapies, including γδ T-cell approaches that overlap with Immatics' ACTallo platform. Comparable technology and indication focus.
- Allogene Therapeutics: Direct competitor in allogeneic (off-the-shelf) cell therapy with gene-edited platforms — overlapping with Immatics' ACTallo allogeneic γδ T-cell strategy. Comparable in modality and cell engineering approach.
- Immunocore Holdings: Direct competitor in TCR-based immunotherapies, with approved tebentafusp (TCR bispecific) in uveal melanoma — directly competing with Immatics' anzu-cel in the same indication. Closely comparable in target class (TCR) and indication focus.
Emerging players
- Moderna: Active collaboration partner (PRAME combination development, 2023) and potential combination-therapy partner or competitor in PRAME-directed cancer vaccines. Comparable adjacency through shared PRAME target.
- CRISPR Therapeutics: Gene-editing cell therapy company with emerging oncology programs; partner of Immatics' allogeneic collaborator Editas Medicine historically. Comparable in cell therapy modality and ex vivo gene editing approach.
Broad incumbents
- Kite Pharma (Gilead Sciences): Established cell therapy leader (Yescarta, Tecartus) expanding into solid tumor indications. Relevant as a broad incumbent that competes for the same commercial infrastructure, payer access, and treatment center relationships.
- Bristol Myers Squibb: Major biopharmaceutical company that was Immatics' largest collaboration partner (terminated 2024) and remains an equity holder. Competes broadly in oncology immunotherapy and could re-enter as a competitor or future commercial partner.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
immatics biotechnologies social profiles
Digital presenceimmatics biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
immatics biotechnologies leadership team
Management profileNumber of profiles
Profiles18 records
immatics biotechnologies subsidiaries and ownership
Company hierarchySubsidiaries1 record
immatics biotechnologies funding detail
Funding detailFunding overview
Funding rounds17 records
Investors33 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
immatics biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about immatics biotechnologies
What does immatics biotechnologies do?
Immatics is a clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies that target the PRAME tumor antigen across multiple modalities. Its commercial lead asset, anzu-cel (IMA203), is being advanced through a Phase 3 SUPRAME trial for advanced melanoma with a BLA submission targeted in H1 2027 and US commercial launch planned for H2 2027. The portfolio also includes PRAME and MAGEA4/8 TCR bispecifics (IMA402, IMA401), an allogeneic γδ T-cell platform (ACTallo), and proprietary target-discovery and TCR-engineering platforms (XPRESIDENT, XCEPTOR, XCUBE), supported by an in-house GMP cell-therapy manufacturing facility in Houston.
Is immatics biotechnologies a public or private company?
immatics biotechnologies is a public company. It is classified as public and is currently operating.
When was immatics biotechnologies founded?
immatics biotechnologies was founded in 2000. It employs 501 to 1,000 people.
Where is immatics biotechnologies based?
immatics biotechnologies is headquartered in Tübingen, Germany, in the Europe region.
How does immatics biotechnologies make money?
Two revenue lines are on record. Collaboration/Partnership Revenue is the primary driver. The others are future Product Sales.
Who are immatics biotechnologies's main competitors?
Direct peers on record are Iovance Biotherapeutics, Fate Therapeutics, Adaptimmune Therapeutics, Cellectis, Allogene Therapeutics and Immunocore Holdings. Emerging players are Moderna and CRISPR Therapeutics. Broad incumbents are Kite Pharma (Gilead Sciences) and Bristol Myers Squibb.
Does immatics biotechnologies have an API?
No public API is recorded for immatics biotechnologies.
What industry is immatics biotechnologies in?
immatics biotechnologies's product category is Cancer Immunotherapies. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAABAF, Dendritic Cell & Other APC-based Therapies. Its NAICS code is 325414 and its SIC code is 2836.